VEGFA and atrophic macular degeneration: CATT showed that 1 in 4 patients who needed aggressive anti-VEGF therapy developed some subretinal fibrosis within 2 years [124] and a greater risk of geographic atrophy in nAMD patients 2 to 5 years after start of therapy [125].